Nuvectis Pharma Secures $14M to Accelerate Precision Oncology Innovations

We are excited to share that Nuvectis Pharma, Inc., a cutting-edge clinical-stage biopharmaceutical company dedicated to transforming oncology care, has successfully raised $14,000,000 in its latest funding round. This significant investment will accelerate the development of Nuvectis’ innovative precision medicines designed to address serious conditions with unmet medical needs in oncology. At the forefront of this initiative are two promising drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule targeting the kinase GCN2, and its clinical development is already underway in trials for platinum-resistant, ARID1a-mutated ovarian cancer—a development pathway that has earned Fast Track Designation by the U.S. FDA. Additionally, NXP800 is being evaluated for the treatment of cholangiocarcinoma in an investigator-sponsored clinical trial led by the esteemed Mayo Clinic, further underscoring its potential and innovation in tackling challenging cancer indications, with Orphan Drug Designation granted by the U.S. FDA emphasizing its promise in a niche area of need. Complementing this, NXP900, an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including targets such as SRC and YES1, is progressing through a Phase 1 dose escalation clinical trial, highlighting the company’s robust pipeline and commitment to addressing diverse oncologic conditions. The fresh infusion of capital will be primarily allocated to advancing clinical trials, optimizing drug development processes, and expanding operational capabilities, thereby reinforcing Nuvectis Pharma’s strategic vision of delivering life-changing therapies to patients in need. This milestone underscores investor confidence in Nuvectis’ potential to make a meaningful impact in the oncological landscape while paving the way for future breakthroughs.